Carbamazepine-induced hyponatremia: assessment of risk factors.
OBJECTIVE
To report a case of carbamazepine-induced acute hyponatremia resulting in seizures.


METHODS
A 44-year-old white woman developed acute hyponatremia and 2 subsequent tonic-clonic seizures after ingesting twice her evening dose of carbamazepine (usual evening dose 600 mg). On admission, her serum sodium level was 122 mEq/L. An infusion of NaCl 0.9% was begun and, within 24 hours, the serum sodium level had returned to her previous level of 136 mEq/L. The woman's preadmission carbamazepine concentration was 8.6 microg/mL, and it was 11.3 micorg/mL on admission. Carbamazepine was withheld and, the following day, the concentration was 5.6 microg/mL. The woman had experienced a similar event 6 months earlier when she also took a large dose of carbamazepine.


CONCLUSIONS
We attributed the acute hyponatremia and seizures to the large increase in dose of carbamazepine in the presence of other risk factors for hyponatremia. Hyponatremia associated with carbamazepine has been well described. The incidence ranges from 1.8% to 40% depending on the patient population studied. Severe hyponatremia in patients treated with monotherapy is uncommon. Several risk factors have been reported to increase the risk of hyponatremia including age >40 years, concomitant use of medications associated with hyponatremia, menstruation, psychiatric condition, surgery, psychogenic polydipsia, and female gender. Treatment is focused on removal of the precipitating factors or discontinuation of carbamazepine therapy. Use of the Naranjo probability scale indicated a highly probable relationship between acute hyponatremia and carbamazepine in our patient.


CONCLUSIONS
Hyponatremia with carbamazepine is well known. The factors associated with increased risk are less understood. An increased awareness of these risks, careful monitoring, and patient education are important in the prevention of neurologic complications.
Kuz
Glenn M
GM
Internal Medicine, Department of Pharmacy Services, University of Washington Medical Center, Seattle, WA 98195, USA. gkuz@u.washington.edu
Manssourian
Alina
A
D000208:Acute Disease; D000328:Adult; D000927:Anticonvulsants / Q000009:adverse effects / Q000627:therapeutic use; D002220:Carbamazepine / Q000009:adverse effects* / Q000097:blood / Q000627:therapeutic use; D062787:Drug Overdose; D004830:Epilepsy, Tonic-Clonic / Q000097:blood / Q000139:chemically induced; D005260:Female; D006801:Humans; D007010:Hyponatremia / Q000097:blood / Q000139:chemically induced*; D007262:Infusions, Intravenous; D012307:Risk Factors; D012964:Sodium / Q000097:blood; D012965:Sodium Chloride / Q000008:administration & dosage / Q000494:pharmacology; D016896:Treatment Outcome
D000927:Anticonvulsants; D002220:Carbamazepine; D012965:Sodium Chloride; D012964:Sodium